At OCTSC, an expert delved into how to optimise patient enrollment to achieve retention and clinical trial success.
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has directed Zydus ...
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has directed Abbott ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering VesCell™ ...
"Sponsors should design failure into clinical trials to support patients" was originally created and published by Clinical ...
Patient-reported outcomes (PROs) are widely used in oncology clinical trials to capture patients’ own perspectives on ...
CDMO conglomerate Almac is pouring $48 million into its eClinical offering via an investment that includes the launch of a ...
The best option is to deploy semi-autonomous models where agents recommend actions, but humans validate and approve those actions. As reliability grows over time, organizations will increase their ...
Sepsis remains one of the leading causes of mortality in hospitalized patients worldwide, and innovative therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback